We are live on ! Find out more
ORTX

Orchard Therapeutics plc American Depositary Shares
ORTX

Delisted

ORTX was delisted on the 23rd of January, 2024.

Back to rankings

50 hedge funds and large institutions have $30.2M invested in Orchard Therapeutics plc American Depositary Shares in 2022 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 7 increasing their positions, 13 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

18% less funds holding

Funds holding: 61 → 50 (-11)

22% less capital invested

Capital invested by funds: $38.9M → $30.2M (-$8.66M)

46% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 13

53% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 17

Holders
50
Holders Change
-11
Holders Change %
-18.03%
% of All Funds
0.84%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
7
Reduced
13
Closed
17
Calls
$10K
Puts
–
Net Calls
+$10K
Net Calls Change
-$1K

Top Buyers

Rank Fund Capital Flow
1
Temasek Holdings
Temasek Holdings
Singapore
+$1.87M
2
TCM
Tang Capital Management
California
+$1.13M
3
Renaissance Technologies
Renaissance Technologies
New York
+$661K
4
UOC
UBS O'Connor
Illinois
+$617K
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$148K

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$3.75M
2
Artisan Partners
Artisan Partners
Wisconsin
-$1.14M
3
SG Americas Securities
SG Americas Securities
New York
-$750K
4
EP
Eversept Partners
New York
-$299K
5
HCA
Harbor Capital Advisors
Illinois
-$168K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$5.03M – – –
Federated Hermes
2
Federated Hermes
Pennsylvania
$4.85M – – –
DM
3
Deerfield Management
New York
$4.06M – – –
CA
4
CHI Advisors
New York
$3.1M – – –
Temasek Holdings
5
Temasek Holdings
Singapore
$2.52M +$1.87M +331,905 +332%
Artisan Partners
6
Artisan Partners
Wisconsin
$1.94M -$1.14M -201,603 -38%
RCM
7
RA Capital Management
Massachusetts
$1.78M -$3.75M -665,390 -69%
TCM
8
Tang Capital Management
California
$1.17M +$1.13M +200,000 New
Renaissance Technologies
9
Renaissance Technologies
New York
$1.16M +$661K +117,226 +144%
AG
10
Artal Group
Luxembourg
$1.05M – – –
JP Morgan Chase
11
JP Morgan Chase
New York
$933K -$59.7K -10,575 -6%
UOC
12
UBS O'Connor
Illinois
$639K +$617K +109,392 New
BlackRock
13
BlackRock
New York
$429K -$9.28K -1,644 -2%
GCP
14
GSA Capital Partners
United Kingdom
$360K +$137K +24,212 +65%
Morgan Stanley
15
Morgan Stanley
New York
$212K +$32.8K +5,810 +19%
Acadian Asset Management
16
Acadian Asset Management
Massachusetts
$153K +$148K +26,168 New
CAM
17
Cormorant Asset Management
Massachusetts
$150K – – –
D.E. Shaw & Co
18
D.E. Shaw & Co
New York
$132K +$128K +22,627 New
Millennium Management
19
Millennium Management
New York
$106K +$102K +18,146 New
New York State Common Retirement Fund
20
New York State Common Retirement Fund
New York
$67K -$118K -20,839 -64%
State Street
21
State Street
Massachusetts
$64K -$553 -98 -0.9%
FA
22
Forefront Analytics
Pennsylvania
$58K -$4.01K -710 -7%
Bank of America
23
Bank of America
North Carolina
$50K -$5.47K -969 -10%
Citigroup
24
Citigroup
New York
$30K +$17.8K +3,151 +164%
Verition Fund Management
25
Verition Fund Management
Connecticut
$29K – – –
1
2 3

ORTX Hedge Fund Activity: Q2 2022 in Review

50 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Orchard Therapeutics plc American Depositary Shares (ORTX) for Q2 2022, worth a combined $30.2M — down 22% from $38.9M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of ORTX and 8 opened new positions — a net loss of 9 holders — while 13 trimmed existing stakes and 7 added.

The largest buyer was Temasek Holdings, adding an estimated $1.87M. The largest seller was RA Capital Management, cutting an estimated $3.75M.

  • 50 institutional investors held Orchard Therapeutics plc American Depositary Shares (ORTX) as of Q2 2022, down from 61 in Q1 2022.
  • Funds reported $30.2M of Orchard Therapeutics plc American Depositary Shares stock for Q2 2022, down 22% quarter-over-quarter.
  • 8 funds opened new Orchard Therapeutics plc American Depositary Shares positions in Q2 2022 and 17 closed out, a net change of -9 holders.
  • The largest Orchard Therapeutics plc American Depositary Shares buyer in Q2 2022 was Temasek Holdings, an estimated $1.87M added.
  • The largest Orchard Therapeutics plc American Depositary Shares seller in Q2 2022 was RA Capital Management, an estimated $3.75M sold.

Based on aggregated 13F filings for Q2 2022.